A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine

Ichiro Ikushima1, Kazuchika Yonenaga1, Hironao Iwakiri2, Hideki Nagoshi2, Haruhito Kumagai2, Yasuyuki Yamashita31Department of Radiology, 2Department of Cardiology, Miyakonojo Medical Association Hospital, Miyakonojo, Japan; 3Department of Diagnostic Radiology, Faculty of Life Sciences, Kumamoto Uni...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ikushima I, Yonenaga K, Iwakiri H, Nagoshi H, Kumagai H, Yamashita Y
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://doaj.org/article/d7edb3373e7d4400aadbafec2ac11df3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d7edb3373e7d4400aadbafec2ac11df3
record_format dspace
spelling oai:doaj.org-article:d7edb3373e7d4400aadbafec2ac11df32021-12-02T02:15:14ZA better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine1179-1470https://doaj.org/article/d7edb3373e7d4400aadbafec2ac11df32011-06-01T00:00:00Zhttp://www.dovepress.com/a-better-effect-of-cilostazol-for-reducing-in-stent-restenosis-after-f-a7739https://doaj.org/toc/1179-1470Ichiro Ikushima1, Kazuchika Yonenaga1, Hironao Iwakiri2, Hideki Nagoshi2, Haruhito Kumagai2, Yasuyuki Yamashita31Department of Radiology, 2Department of Cardiology, Miyakonojo Medical Association Hospital, Miyakonojo, Japan; 3Department of Diagnostic Radiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanPurpose: The purpose of this study was to assess the preventive effect of cilostazol on in-stent restenosis in patients after superficial femoral artery (SFA) stent placement.Materials and methods: Of 28 patients with peripheral arterial disease, who had successfully undergone stent implantation, 15 received cilostazol and 13 received ticlopidine. Primary patency rates were retrospectively analyzed by means of Kaplan–Meier survival curves, with differences between the two medication groups compared by log-rank test. A multivariate Cox proportional hazards model was applied to assess the effect of cilostazol versus ticlopidine on primary patency.Results: The cilostazol group had significantly better primary patency rates than the ticlopidine group. Cumulative primary patency rates at 12 and 24 months after stent placement were, respectively, 100% and 75% in the cilostazol group versus 39%and 30% in the ticlopidine group (P = 0.0073, log-rank test). In a multivariate Cox proportional hazards model with adjustment for potentially confounding factors, including history of diabetes, cumulative stent length, and poor runoff, patients receiving cilostazol had significantly reduced risk of restenosis (hazard ratio 5.4; P = 0.042).Conclusion: This retrospective study showed that cilostazol significantly reduces in-stent stenosis after SFA stent placement compared with ticlopidine.Keywords: cilostazol, ticlopidine, stent, primary patency rate, peripheral arterial disease, superficial femoral arteryIkushima IYonenaga KIwakiri HNagoshi HKumagai HYamashita YDove Medical PressarticleMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol 2011, Iss default, Pp 83-89 (2011)
institution DOAJ
collection DOAJ
language EN
topic Medical technology
R855-855.5
spellingShingle Medical technology
R855-855.5
Ikushima I
Yonenaga K
Iwakiri H
Nagoshi H
Kumagai H
Yamashita Y
A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine
description Ichiro Ikushima1, Kazuchika Yonenaga1, Hironao Iwakiri2, Hideki Nagoshi2, Haruhito Kumagai2, Yasuyuki Yamashita31Department of Radiology, 2Department of Cardiology, Miyakonojo Medical Association Hospital, Miyakonojo, Japan; 3Department of Diagnostic Radiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanPurpose: The purpose of this study was to assess the preventive effect of cilostazol on in-stent restenosis in patients after superficial femoral artery (SFA) stent placement.Materials and methods: Of 28 patients with peripheral arterial disease, who had successfully undergone stent implantation, 15 received cilostazol and 13 received ticlopidine. Primary patency rates were retrospectively analyzed by means of Kaplan–Meier survival curves, with differences between the two medication groups compared by log-rank test. A multivariate Cox proportional hazards model was applied to assess the effect of cilostazol versus ticlopidine on primary patency.Results: The cilostazol group had significantly better primary patency rates than the ticlopidine group. Cumulative primary patency rates at 12 and 24 months after stent placement were, respectively, 100% and 75% in the cilostazol group versus 39%and 30% in the ticlopidine group (P = 0.0073, log-rank test). In a multivariate Cox proportional hazards model with adjustment for potentially confounding factors, including history of diabetes, cumulative stent length, and poor runoff, patients receiving cilostazol had significantly reduced risk of restenosis (hazard ratio 5.4; P = 0.042).Conclusion: This retrospective study showed that cilostazol significantly reduces in-stent stenosis after SFA stent placement compared with ticlopidine.Keywords: cilostazol, ticlopidine, stent, primary patency rate, peripheral arterial disease, superficial femoral artery
format article
author Ikushima I
Yonenaga K
Iwakiri H
Nagoshi H
Kumagai H
Yamashita Y
author_facet Ikushima I
Yonenaga K
Iwakiri H
Nagoshi H
Kumagai H
Yamashita Y
author_sort Ikushima I
title A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine
title_short A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine
title_full A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine
title_fullStr A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine
title_full_unstemmed A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine
title_sort better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine
publisher Dove Medical Press
publishDate 2011
url https://doaj.org/article/d7edb3373e7d4400aadbafec2ac11df3
work_keys_str_mv AT ikushimai abettereffectofcilostazolforreducinginstentrestenosisafterfemoropoplitealarterystentplacementincomparisonwithticlopidine
AT yonenagak abettereffectofcilostazolforreducinginstentrestenosisafterfemoropoplitealarterystentplacementincomparisonwithticlopidine
AT iwakirih abettereffectofcilostazolforreducinginstentrestenosisafterfemoropoplitealarterystentplacementincomparisonwithticlopidine
AT nagoshih abettereffectofcilostazolforreducinginstentrestenosisafterfemoropoplitealarterystentplacementincomparisonwithticlopidine
AT kumagaih abettereffectofcilostazolforreducinginstentrestenosisafterfemoropoplitealarterystentplacementincomparisonwithticlopidine
AT yamashitay abettereffectofcilostazolforreducinginstentrestenosisafterfemoropoplitealarterystentplacementincomparisonwithticlopidine
AT ikushimai bettereffectofcilostazolforreducinginstentrestenosisafterfemoropoplitealarterystentplacementincomparisonwithticlopidine
AT yonenagak bettereffectofcilostazolforreducinginstentrestenosisafterfemoropoplitealarterystentplacementincomparisonwithticlopidine
AT iwakirih bettereffectofcilostazolforreducinginstentrestenosisafterfemoropoplitealarterystentplacementincomparisonwithticlopidine
AT nagoshih bettereffectofcilostazolforreducinginstentrestenosisafterfemoropoplitealarterystentplacementincomparisonwithticlopidine
AT kumagaih bettereffectofcilostazolforreducinginstentrestenosisafterfemoropoplitealarterystentplacementincomparisonwithticlopidine
AT yamashitay bettereffectofcilostazolforreducinginstentrestenosisafterfemoropoplitealarterystentplacementincomparisonwithticlopidine
_version_ 1718402622487003136